SCHEMBL7059669

SCHEMBL7059669

COc1ccc(S(=O)(=O)N2CCN(S(C)(=O)=O)[C@@H](C)[C@@H]2C(=O)O)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 12/20 0.55
MMP3 P08254 11/20 0.55
MMP7 P09237 9/20 0.53
MMP13 P45452 8/20 0.53
MMP9 P14780 8/20 0.53
ADAM17 P78536 1/20 0.52
LMNA P02545 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
TSHR P16473 1/20 0.49
RECQL P46063 1/20 0.49
MAPT P10636 1/20 0.49
MMP2 P08253 2/20 0.48
MMP8 P22894 1/20 0.48
NPC1 O15118 1/20 0.48
PKM P14618 1/20 0.48
PKLR P30613 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7057703 0.87 MMP1 (0.68) MMP1MMP3MMP7MMP13MMP9
SCHEMBL7053311 0.87 MMP1 (0.68) MMP1MMP3MMP7MMP13MMP9
SCHEMBL7056730 0.81 MMP1 (0.53) MMP1MMP3MMP7MMP13MMP9
SCHEMBL7054410 0.80 MMP1 (0.57) MMP1MMP3MMP7MMP13MMP9
SCHEMBL7057487 0.76 MMP1 (0.49) MMP1MMP3MMP7MMP13MMP9
SCHEMBL6075816 0.76 MMP1 (0.60) MMP1MMP3MMP7MMP13MMP9
SCHEMBL7248829 0.75 MMP3 (0.50) MMP1MMP3MMP7MMP13MMP9
SCHEMBL8517198 0.75 MMP3 (0.50) MMP1MMP3MMP7MMP13MMP9
SCHEMBL7248830 0.75 MMP3 (0.50) MMP1MMP3MMP7MMP13MMP9
SCHEMBL7389960 0.74 MMP1 (0.57) MMP1MMP3MMP7MMP13MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030060473-A1 Piperazine compounds as inhibitors of MMP or TNF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-27 US disclosed
US-6489324-B2 TREATING STROKE, ARHTRITIS, CANCER, TISSUE ULCERATION, DECUBITIS ULCER, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCLERITIS, PSORIASIS, AIDS, SEPSIS, AND SEPTIC SHOCK. FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-03 US disclosed
US-20020128270-A1 Piperazine compounds as inhibitors of MMP or TNF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-09-12 US disclosed
US-6333324-B1 FOR THERAPY AND PROPHYLAXIS OF MATRIX METALLOPROTEINASES (MMP) OR TUMOR NECROSIS FACTOR .ALPHA. (TNF.ALPHA.), MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-12-25 US disclosed
EP-0948489-A1 PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-10-13 EP disclosed
WO-1998027069-A1 PIPERAZINE COMPOUNDS AS INHIBITORS OF MMP OR TNF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128270-A1 Piperazine compounds as inhibitors of MMP or TNF MMP1, MMP2, TNF MMP1 1/4885MMP3 7/4885MMP7 19/4885
US-20030060473-A1 Piperazine compounds as inhibitors of MMP or TNF MMP2, MMP1, TNF MMP1 2/4885MMP3 7/4885MMP7 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.